REGENXBIO to Participate in Upcoming Investor Conferences
RGNXROCKVILLE, Md., Aug. 28, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: 2025 Wells Fargo Healthcare Conference 1x1 Investor Meetings: Thursday, September 4 Location: Boston, MA Morgan Stanley 23rd Annual Global...
Regenx Provides Bi-Weekly Update on Status of Management Cease Trade Order
RGNXRegenx confirms audit underway, filings expected Sept 29, 2025; no material changes or financial concerns to report.
REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II
RGNXRGX-121 would be the first and only potential one-time commercially-available therapy designed to directly address the underlying genetic cause of Hunter syndrome, if approved Commercial launch plans remain on track REGENXBIO plans to present updated pivotal data during the ICIEM meeting...
Regenx Provides Bi-Weekly Update on Status of Management Cease Trade Order
RGNXRegenx provides bi-weekly update on MCTO status; expects to file 2025 Annual Filings by September 29. No material changes or defaults reported.
REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy
RGNXA pivotal Phase IIb/III clinical trial using suprachoroidal delivery for treatment of diabetic retinopathy will be initiated New Phase II ALTITUDE® trial data demonstrate a durable safety and efficacy profile observed through two years with a single, in-office injection of surabgene...
A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts
RGNXEarly Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer
RGNXRegenXBio's RGX-202 gene therapy improved function in Duchenne patients at 9 and 12 months, supporting a 2026 BLA filing and 2027 launch.
Regenxbio Announced New Interim Data From The Phase 1/2 Affinity Duchenne Trial. Updates Include Positive Functional, Safety And Biomarker Data For RGX-202, The Functional Data Demonstrate Consistent Benefit Among Dose Level 2 Participants At 9 And 12 Mon
RGNXREGENXBIO Announces Closure Of Non-Dilutive, Limited Recourse Royalty Bond Agreement Of Up To $250M With Healthcare Royalty
RGNXREGENXBIO Announces FDA Acceptance And Priority Review Of BLA For RGX-121 For Mucopolysaccharidosis II
RGNXRegenxbio Q1 EPS $0.12 Misses $0.22 Estimate, Sales $89.01M Miss $101.97M Estimate
RGNXWhat to Expect from Regenxbio's Earnings
RGNXGoldman Sachs Maintains Neutral on Regenxbio, Lowers Price Target to $12
RGNXHC Wainwright & Co. Reiterates Buy on Regenxbio, Maintains $34 Price Target
RGNXHC Wainwright & Co. Reiterates Buy on Regenxbio, Maintains $34 Price Target
RGNXChardan Capital Maintains Buy on Regenxbio, Maintains $52 Price Target
RGNXRegenxbio Touts Positive Biomarker Data From Duchenne Muscular Dystrophy Gene Therapy Trial
RGNXRegenxbio's RGX-202 gene therapy shows promising results in Duchenne muscular dystrophy, with high microdystrophin levels and a well-tolerated safety profile.
REGENXBIO Presents Interim Data From Two Patients In Phase I/II Portion Of AFFINITY DUCHENNE Trial Of RGX-202 At 2025 Muscular Dystrophy Association Clinical & Scientific Conference
RGNXHC Wainwright & Co. Maintains Buy on Regenxbio, Lowers Price Target to $34
RGNXA Glimpse Into The Expert Outlook On Regenxbio Through 5 Analysts
RGNXChardan Capital Maintains Buy on Regenxbio, Maintains $52 Price Target
RGNXMorgan Stanley Maintains Overweight on Regenxbio, Raises Price Target to $24
RGNXREGENXBIO Expects Cash Runway To Fund Its Operations Into H2 Of 2026
RGNXRegenxbio Q4 2024 GAAP EPS $(1.01) Beats $(1.15) Estimate, Sales $21.21M Miss $23.75M Estimate
RGNXREGENXBIO Plans To Present New Interim Biomarker Data From Phase I/II Portion Of AFFINITY DUCHENNE Trial Of RGX-202 At 2025 MDA Clinical & Scientific Conference
RGNXRegenxbio Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
RGNXHC Wainwright & Co. Reiterates Buy on Regenxbio, Maintains $36 Price Target
RGNXRegenXBio shares are trading higher after the company announced a partnership with Nippon Shinyaku in a $810 million deal.
RGNXREGENXBIO Partners with Nippon Shinyaku in $810M Deal for Hunter and Hurler Syndrome Therapies
RGNXChardan Capital Maintains Buy on Regenxbio, Maintains $52 Price Target
RGNXWhat's Going On With REGENXBIO Shares Monday?
RGNXREGENXBIO stock is trading higher on Monday after the company reached a critical point in its trial for Duchenne gene therapy.
REGENXBIO Doses First Patient in Pivotal Trial for Duchenne Gene Therapy
RGNX5 Analysts Have This To Say About Regenxbio
RGNXMorgan Stanley Assumes Regenxbio at Overweight, Announces Price Target of $22
RGNXRegenxbio Q3 EPS $(1.17) Misses $(1.12) Estimate, Sales $24.20M Beat $23.59M Estimate
RGNXWhat 4 Analyst Ratings Have To Say About Regenxbio
RGNXWithin the last quarter, Regenxbio (NASDAQ:RGNX) has observed the following analyst ratings:
Morgan Stanley Maintains Overweight on Regenxbio, Raises Price Target to $52
RGNXRegenxbio Q1 GAAP EPS $(1.79) Misses $(1.32) Estimate, Sales $22.20M Miss $29.21M Estimate
RGNX